no spam, unsubscribe anytime.
The University of Michigan Comprehensive Cancer Center's new Translational Oncology Program focuses on speeding up the transistion from research to treatment through better communication among different disciples.
“The University of Michigan is well known for its strength in basic science. Now, we have the opportunity with the Translational Oncology Program to really make a difference in patients’ lives -- which is the real reason we are all here,” says Diane Simeone, M.D., who has been named director of the new program.
As many as forty investigators will eventually be part of this new program, including teams focused on experimental therapeutics, cancer stem cells, molecular imaging and genomics.
“The North Campus Research Complex offers a unique opportunity for researchers across campus to talk with each other and collaborate in ways they have never had before. We also offer core services that help facilitate the process of biomedical research and produce results that can be quickly translated into benefits for patients,” saud Colin S. Duckett, Ph.D., director of program development at the North Campus Research Complex.
Through a partnership with the Ross School of Business and the Medical School’s Business Development team, leaders of the program plan to increase interactions with industry and establish more biomedical companies designed to facilitate moving scientific discoveries into the clinic.